Abstract 916P
Background
Radiation-induced temporal lobe injury (TLI) is one of the most common radiation-induced toxicities in nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT), especially in patients with cavernous sinus invasion whose planning target volume of nasopharynx (PTVnx) and temporal lobe (TL) is often overlapped. We named the overlap area as the sub-volume of PTVnx and TL (PTVsv-TL) and gave it independent prescription dose, and investigated its efficacy and feasibility in this study.
Methods
From 2015 to 2020, T4 stage NPC patients with cavernous sinus invasion treated by independent prescription dose of PTVsv-TL (60-64Gy) were enrolled in study group, while T4 stage patients with cavernous sinus invasion treated by prescription dose recommended as international guidelines were enrolled in control group. The primary endpoint is the 3-year cumulative incidence of TLI, and secondary endpoints included dose parameters of TL, local recurrence rate and pattern, regional recurrence-free survival (RRFS), distant metastasis-free survival (DMFS) and overall survival (OS). SPSS 25.0 was used for statistical analysis.
Results
Totally, 137 and 357 patients were enrolled in the study group and control group, respectively. The median follow-up time was 33.0 months (inter-quartile range, 22.0-44.0 months). 17.6% patients (87/494) were diagnosed as TLI by MRI. The 3-year cumulative incidence of TLI in the study and control group were 15.3% and 28.5% (P=0.006). The dose parameters of TLs in two groups were as follows: D2, D0.5cc, D1cc and D2cc were 62.0 vs 70.5Gy, 66.1 vs 73.2Gy, 64.1 vs 72.1Gy, and 61.8 vs 70.0Gy (all P<0.001). The 3-year cumulative local recurrence rate were 6.2% and 10.4% in the study and control groups (P=0.170), with 2 cases of marginal failure in each group and none out-field failure. The 3-year PFS and OS rates were 87.8% vs 90.4% (P=0.275), 86.3% vs 88.2% (P=0.649), and 97.2% vs 97.3% (P=0.581).
Conclusions
Giving independent prescription dose to PTVsv-TL could significantly reduce the irradiated dose of TLs and decrease the incidence of TLI, meanwhile achieved satisfactory local control and long-term survival. Further prospective study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12